On July 22, 2025, E2joy co-organized the seminar titled “Smart Biopharmaceutical Manufacturing: Trends and Challenges in Aseptic Filling and Integrated Services,” hosted by the Taiwan Parenteral Drug Association (TPDA) and Mycenax Biotech. The event took place in Zhunan and drew a large audience from the biotechnology and pharmaceutical industries.

The morning session featured a series of in-depth presentations and discussions led by Mycenax’s team of experts. Topics included end-to-end process integration from drug research to product launch, with a focus on solutions aimed at improving quality and efficiency. The talks also addressed formulation development and process optimization to enhance the success rate and stability of aseptic filling, as well as challenges in transferring analytical technologies into large-scale manufacturing.

The focus then shifted to innovations in aseptic processing, including the use of ready-to-use (RTU) components in compliance with Annex 1 guidelines, the implementation of intelligent equipment, and the practical challenges and prospects of integrated service models. The event sparked engaging interactions and discussions among the audience, highlighting strong interests within the the industry in the digital transformation of pharmaceutical manufacturing.

In the afternoon, participants visited Mycenax’s facilities to see and understand the practical applications of aseptic filling and process automation. The guided tour and on-site demonstrations left a strong impression of Mycenax’s technical expertise and innovative capabilities.

This event not only facilitated valuable technical exchange across the industry but also strengthened our collaborations with key partners. We extend our sincere thanks to Chairman Wu Pai-Feng of TPDA, and Ms. Pei-Chun Chen, Chairperson and CEO of Mycenax for their leadership, and to all participants for their support. We look forward to continuing to work together in advancing Taiwan’s biopharmaceutical industry into a new era of smart manufacturing.